SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives

SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives

Abstract Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as important agents for the treatment of type 2 diabetes mellitus (T2DM). SGLT2 inhibitors have been associated with improved cardiovascular outcomes, not only through their immediate hemodynamic effects—such as glycosuria and...

Full description

Bibliographic Details
Main Authors: Cassandra Morciano, Shawn Gugliandolo, Umberto Capece, Gianfranco Di Giuseppe, Teresa Mezza, Gea Ciccarelli, Laura Soldovieri, Michela Brunetti, Adriana Avolio, Amelia Splendore, Alfredo Pontecorvi, Andrea Giaccari, Francesca Cinti
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes
Metabolism
Adipose organ
SGLT-2i
Precision medicine
Epicardial adipose tissue
Online Access:https://doi.org/10.1186/s12933-024-02539-x

Internet

https://doi.org/10.1186/s12933-024-02539-x

Similar Items